Ann: Regulatory Approval for Remplir Nerve Repair Device, page-39

Just a little insight into the potential of why this is such a big step for the company, against the naval gazers moaning on about a share price they themselves sold down as holders (there are very little short sales - I often short sell companies, but shorting OCC would be idiotic reward vs risk payoff).

The Aussie market is small, but OCC are well ahead on US mkt and this approval only adds impetus. There are reportedly 20 million Americans suffering from peripheral nerve damage in the US alone. Nerve injuries see a $150 billion expenditure a year in the US alone. Only 51.6% percent recover satisfactory nerve recovery! This is a massive market for OCC:


https://www.hindawi.com/journals/bmri/2014/698256/

(Some good background reading for people on nerve repair options, albeit a little dated)